Get the Stockscreener App
77.10
1.68%
1.3458
Incyte Corp stock is traded at $77.10, with a volume of 553.34K.
It is up +1.68% in the last 24 hours and up +14.12% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$75.75
Open:
$75.77
24h Volume:
553.34K
Relative Volume:
0.32
Market Cap:
$14.80B
Revenue:
$3.86B
Net Income/Loss:
$97.30M
P/E Ratio:
40.79
EPS:
1.89
Net Cash Flow:
$-139.52M
1W Performance:
+4.65%
1M Performance:
+14.12%
6M Performance:
+43.27%
1Y Performance:
+40.42%
1-Day Range:
$75.34
$77.12
1-Week Range:
$72.50
$77.12
52-Week Range:
$50.35
$77.12
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Incyte stock soars to 52-week high, hits $76.58 - Investing.com
Robeco Institutional Asset Management B.V. Purchases 70,596 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
NJ Judge Blocks Sun Pharma From Launching Hair Loss Drug - Law360
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte (NASDAQ:INCY) Sets New 52-Week HighWhat's Next? - MarketBeat
Incyte Corp (INCY)'s Winning Formula: Financial Metrics and Comp - GuruFocus.com
Incyte Co. (NASDAQ:INCY) Stock Holdings Trimmed by State of Alaska Department of Revenue - MarketBeat
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday - MSN
Incyte Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Incyte (NASDAQ:INCY) Posts Quarterly Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - MSN
Incyte Corporation (NASDAQ:INCY) Q3 2024 Earnings Call Transcript - Insider Monkey
14,631 Shares in Incyte Co. (NASDAQ:INCY) Acquired by Integrated Advisors Network LLC - MarketBeat
Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Earnings call: Incyte reports robust growth and pipeline progress - Investing.com
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock - Yahoo Finance
Incyte (NASDAQ:INCY) Price Target Raised to $71.00 - MarketBeat
Incyte shares target upgraded, outperform rating on strong Q3 sales - Investing.com
Incyte stock target raised, underperform rating held on Jakafi revenue outlook - Investing.com
Incyte shares target raised, rating held on strong 3Q results - Investing.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Incyte Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Incyte stock sees upside with strong Jakafi performance and robust pipeline—Citi - Investing.com
Incyte (INCY) PT Raised to $87 at Leerink Partners - StreetInsider.com
Incyte (INCY) PT Raised to $97 at Citi - StreetInsider.com
Incyte Co. (NASDAQ:INCY) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Incyte: Q3 Earnings Snapshot - The Pioneer
Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Jefferies lifts Incyte target to $84, maintains buy on Q3 beat - Investing.com
Incyte (INCY) PT Raised to $84 at Jefferies - StreetInsider.com
BofA raises Incyte stock to buy, price target to $90 from $68 - Investing.com
Incyte Rallies on Strong Q3 Revenue, Jakafi Outlook Lifted - Yahoo Finance
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura - Yahoo Finance
Incyte Raises Jakafi Sales Forecast, Surpassing Expectations - Finimize
Incyte stock hits 52-week high at $70.44 amid robust growth - Investing.com
Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings - Yahoo Finance
Incyte raises 2024 sales forecast for top-selling drug Jakafi - Reuters
Incyte (INCY) Q3 Earnings Miss Estimates - Yahoo Finance
Incyte Corp Q3 2024 Earnings: Revenue Surges to $1,138 Million, EPS at $0.55, Exceeding Estimates - GuruFocus.com
Incyte Reports 2024 Third Quarter Financial Results And Provides Updates On Key Clinical Programs - XM
Incyte earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
Incyte earnings beat by $0.04, revenue topped estimates - Investing.com
Incyte Q3 24 Earnings Conference Call At 8:00 AM ET - Nasdaq
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs - Yahoo Finance
Forsta AP Fonden Purchases 34,800 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte's SWOT analysis: biotech stock faces patent cliff as pipeline potential grows - Investing.com
Incyte Co. (NASDAQ:INCY) Shares Sold by Mediolanum International Funds Ltd - MarketBeat
Incyte Corp. stock rises Thursday, still underperforms market - MarketWatch
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List - Yahoo Finance
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):